GSK presents case to ex­pand use of its lu­pus drug in pa­tients with kid­ney dis­ease, but the field is evolv­ing. How long will the mo­nop­oly last?

In 2011, Glax­o­SmithK­line’s Benlysta be­came the first bi­o­log­ic to win ap­proval for lu­pus pa­tients. Nine years on, the British drug­mak­er has un­veiled de­tailed pos­i­tive re­sults …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.